Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Melanie R Baxter"'
Autor:
James A. Karlowsky, Andrew J. Walkty, Melanie R. Baxter, Heather J. Adam, Philippe R. S. Lagacé-Wiens, Frank Schweizer, Denice Bay, Joseph P. Lynch, Michael R. Mulvey, George G. Zhanel
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 4 (2022)
ABSTRACT Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019). Overall, 98.3% of isolates remained cefiderocol susceptible (MIC,
Externí odkaz:
https://doaj.org/article/5077a3bc87b34505b0c469eceb87ec6c
Autor:
Morgan A Alford, James A Karlowsky, Heather J Adam, Melanie R Baxter, John Schellenberg, Alyssa R Golden, Irene Martin, Walter Demczuk, Michael R Mulvey, George G Zhanel
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:i8-i16
Objectives To assess the antimicrobial susceptibility of 14 138 invasive Streptococcus pneumoniae isolates collected in Canada from 2011 to 2020. Methods Antimicrobial susceptibility testing was performed using the CLSI M07 broth microdilution refere
Autor:
Heather J Adam, James A Karlowsky, Melanie R Baxter, John Schellenberg, Alyssa R Golden, Irene Martin, Walter Demczuk, Michael R Mulvey, George G Zhanel
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:i17-i25
Objectives To investigate the levels of MDR in the predominant serotypes of invasive Streptococcus pneumoniae isolated in Canada over a 10 year period. Methods All isolates were serotyped and had antimicrobial susceptibility testing performed, in acc
Autor:
John J Schellenberg, Heather J Adam, Melanie R Baxter, James A Karlowsky, Alyssa R Golden, Irene Martin, Walter Demczuk, Michael R Mulvey, George G Zhanel
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:i37-i47
Background As pneumococci evolve under vaccine, antimicrobial and other selective pressures, it is important to track isolates covered by established (PCV10, PCV13 and PPSV23) and new (PCV15 and PCV20) vaccine formulations. Objectives To compare inva
Autor:
Andrew Walkty, James A Karlowsky, Philippe Lagace-Wiens, Melanie R Baxter, Heather J Adam, George G Zhanel
Publikováno v:
JAC-antimicrobial resistance. 4(6)
Objectives To investigate in vitro susceptibility patterns of bacterial pathogens recovered from the urine of outpatients (isolates from outpatient clinics or emergency departments) and hospital inpatients across Canada from 2009 to 2020 as part of t
Autor:
Walter Demczuk, James A. Karlowsky, Michael R. Mulvey, George G. Zhanel, Alyssa R Golden, Melanie R. Baxter, Heather J. Adam, Irene Martin
Publikováno v:
Vaccine. 39:5474-5483
The population of pneumococci circulating in Canada is constantly shifting under the pressures of antimicrobial and conjugate vaccine use. A new 15-valent pneumococcal conjugate vaccine (PCV), containing PCV-13 serotypes plus additional serotypes 22F
Autor:
Andrew Walkty, Melanie R. Baxter, Philippe Lagacé-Wiens, Heather J. Adam, George G. Zhanel, Robert M Taylor, James A. Karlowsky
Publikováno v:
J Assoc Med Microbiol Infect Dis Can
Background: Community-acquired pneumonia (CAP) is a significant global health concern. Pathogens causing CAP demonstrate increasing resistance to commonly prescribed empiric treatments. Resistance in Streptococcus pneumoniae, the most prevalent bacte
Autor:
Andrew J Walkty, James A Karlowsky, Melanie R Baxter, Philippe R S Lagace-Wiens, Heather J Adam, George G Zhanel
Publikováno v:
The Journal of antimicrobial chemotherapy. 77(12)
Introduction There are limited oral antimicrobial options for the treatment of urinary infections caused by ESBL-producing and MDR Enterobacterales. Sulopenem is an investigational thiopenem antimicrobial that is being developed as both an oral and I
Autor:
Maxime Dube, Sergio Borgia, James A. Karlowsky, Andrew Walkty, Jean-Francois Tessier, Michel Savoie, Robert E. Ariano, Gordon Dow, Rita Dhami, Melanie R. Baxter, Carlos Cervera, Matteo Bassetti, Rosemary Zvonar, Neal Irfan, George G. Zhanel, Justin Kosar
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 25, Iss, Pp 346-350 (2021)
Objectives Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. We report the use of ceftolozane/tazobactam in Canada using a national registry. Methods The CLEAR registry uses REDC
Autor:
James A Karlowsky, Melanie R Baxter, Andrew J Walkty, Philippe R S Lagacé-Wiens, Denice Bay, Heather J Adam, George G Zhanel
Publikováno v:
The Journal of antimicrobial chemotherapy. 77(11)
Background Multiple susceptible breakpoints are published to interpret fosfomycin MICs: ≤64 mg/L for Escherichia coli and Enterococcus faecalis grown from urine (CLSI M100); ≤32 mg/L for Enterobacterales and staphylococci when parenteral fosfomyc